Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -9.95
- Piotroski Score 3.00
- Grade Buy
- Symbol (GTH)
- Company Genetron Holdings Limited
- Price $4.03
- Changes Percentage (0.12%)
- Change $0.01
- Day Low $4.02
- Day High $4.05
- Year High $4.05
Genetron Holdings Limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. The company offers diagnosis and monitoring services, and early screening services through laboratory developed tests services. It also provides in-vitro diagnostic products, including 8-gene lung cancer assay, an IVD assay product to detect lung cancer; Genetron 3D biochip reading instrument; Genetron S5, a semiconductor-based NGS system, which detects the nucleotide through detecting the change in pH; Genetron Chef System; Genetron S2000 platform, a production-scale sequencer; and Onco PanScan, a genomic profiling service for various solid tumors. In addition, it offers IDH1 and TERT gene assays for glioma; thyroid basic assay for thyroid tumor; platelet-derived growth factor receptor alpha assay for GIST cancer; and HCCscan, a qPCR-based assay to detect hepatocellular carcinoma. Further, it provides development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies worldwide. The company has a strategic partnership with JD Health to create solutions for full-cycle cancer management. Genetron Holdings Limited was founded in 2015 and is headquartered in Beijing, the People's Republic of China.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 01/17/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Buy
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$3.62
- Trailing P/E Ratio -1.1118784530387
- Forward P/E Ratio -1.1118784530387
- P/E Growth -1.1118784530387
- Net Income $-883,889,000
Income Statement
Quarterly
Annual
Latest News of GTH
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
West Coast Rattled by Hurricane-Strength Winds and Blizzard Warnings
A powerful storm hit Northern California, causing widespread damage and power outages. The storm brought heavy rain and strong winds, affecting transportation and prompting warnings of flooding and fa...
By The New York Times | 1 day ago -
Charter Communications (CHTR): Strengthening Subscriber Base with Strategic Partnerships
Ken Griffin's hedge fund Citadel Investment Group has seen remarkable success with over $518 billion in assets. Citadel Securities, valued at $22 billion, has revolutionized trading. Griffin is a majo...
By Yahoo! Finance | 1 day ago -
Tottenham appeal against length of Bentancur's ban for Son comments
Tottenham Hotspur's Rodrigo Bentancur was banned for seven games by the FA for making offensive remarks about teammate Son Heung-min. Spurs appealed the severity of the suspension, while Bentancur apo...
By The Guardian | 1 day ago
